RxDoctor Payments DataLook up a doctor →

David Young, MD

Interventional Cardiology · Jackson, MSNPI 1366487365

Payments from drug & device makers

$28,090in general payments, 2019–2025

Across 391 payments — averaging $71.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$18K
  • Angiodynamics, Inc.$2K
  • Novartis$2K
  • Abiomed$2K
  • Philips North America LLC$818
  • Shockwave Medical, Inc$701
  • plus $3K from 30 others

What the payments were for

  • Speaking & faculty fees$14,75053%
  • Travel & lodging$1,5786%
  • Food & beverage$11,76242%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,090 in reported general payments places this provider in the 75th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,080,939
Medicare patients
1,965
Services billed
36,370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban744$593,890
XareltoRivaroxaban485$393,941
EntrestoSacubitril/Valsartan484$381,959
JardianceEmpagliflozin262$187,007
Repatha SureclickEvolocumab130$97,629
FarxigaDapagliflozin Propanediol124$96,333
BrilintaTicagrelor146$75,042
Metoprolol Succinate965$12,303
Rosuvastatin Calcium1,094$10,181
ClopidogrelClopidogrel Bisulfate1,008$8,236
Ranolazine ErRanolazine87$6,701
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide202$6,597
Carvedilol1,092$6,407
Praluent PenAlirocumab13$6,337
Atorvastatin Calcium776$5,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$593,890744 claims
Johnson & JohnsonXarelto$176$393,941485 claims
NovartisEntresto$1,742$381,959484 claims
Boehringer IngelheimJardiance$440$187,007262 claims
AstraZenecaFarxiga, Brilinta$383$171,375270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →